20 / 38
Liposomal-encapsulated irinotecan has benefits
Kalra AV, et al. Cancer Res 2014;74:7003
Advantage of nal-IRI encapsulation
Non-liposomal
irinotecan
nal-IRI
Prolonged exposure in plasma
Irinotecan and SN-38
plasma levels cleared from
circulation within 8 h
Irinotecan and SN-38
remained in circulation
for >50 h
Prolonged exposure in tumours
>90% irinotecan was
cleared from tumours
within 24 h
SN-38 exposure in
tumours <48 h
Irinotecan levels persisted
above 10,000 nmol/l for 168 h
in tumours
Prolonged SN-38 exposure
above activity threshold for
up to168 h
Dose needed to achieve similar
SN-38 exposure in plasma
and tumours
50 mg/kg
10 mg/kg
Enhanced tumour growth inhibition
in animal models
~40%
~110%